Ivermectin SARS - PMC

Mohsen Nabi-Afjadi, Fatemeh Mohebi, Hamidreza Zalpoor, Fatemeh Aziziyan, Abdullatif Akbari, Hemen Moradi-Sardareh, Elham Bahreini, Amir Mansour Moeini, Hossein Effatpanah

Inflammopharmacology. 2023; 31(1): 21–35. Published online 2023 Jan 7. doi: 10.1007/s10787-022-01129-1

PMCID:: PMC9823263

Abstract Article PDF–1.1M

Select item 88174754.

Repurposing the drug, ivermectin, in COVID-19: toxicological points of view

Farshad M. Shirazi, Roya Mirzaei, Samaneh Nakhaee, Amir Nejatian, Shokouh Ghafari, Omid Mehrpour

Eur J Med Res. 2022; 27: 21. Published online 2022 Feb 5. doi: 10.1186/s40001-022-00645-8

PMCID:: PMC8817475

Abstract Article PDF–1.2M

Select item 80134825.

A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS‐CoV‐2

Robert T. Kinobe, Leigh Owens

Fundam Clin Pharmacol. 2021 Apr; 35(2): 260–276. Published online 2021 Jan 28. doi: 10.1111/fcp.12644

PMCID:: PMC8013482

Abstract Article PDF–1.5M

Select item 75369806.

Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment

Na Li, Lingfeng Zhao, Xianquan Zhan

J Cell Physiol. 2021 Apr; 236(4): 2959–2975. Published online 2020 Sep 22. doi: 10.1002/jcp.30055

PMCID:: PMC7536980

Abstract Article PDF–4.7M

Select item 87653257.

Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells

Nilima Dinesh Kumar, Bram M. ter Ellen, Ellen M. Bouma, Berit Troost, Denise P. I. van de Pol, Heidi H. van der Ende-Metselaar, Djoke van Gosliga, Leonie Apperloo, Orestes A. Carpaij, Maarten van den Berge, Martijn C. Nawijn, Ymkje Stienstra, Izabela A. Rodenhuis-Zybert, Jolanda M. Smit

Antimicrob Agents Chemother. 2022 Jan; 66(1): e01543-21. Prepublished online 2021 Oct 11. Published online 2022 Jan 18. doi: 10.1128/AAC.01543-21

PMCID:: PMC8765325

Abstract Article PDF–1.1M

Select item 75777038.

The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?

David A. Jans, Kylie M. Wagstaff

Biochem Biophys Res Commun. 2021 Jan 29; 538: 163–172. Published online 2020 Oct 21. doi: 10.1016/j.bbrc.2020.10.042

PMCID:: PMC7577703

Abstract Article PDF–794K

Select item 101271649.

Prophylactic administration of ivermectin attenuates SARS-CoV-2 induced disease in a Syrian Hamster Model

Takayuki Uematsu, Tomomi Takano, Hidehito Matsui, Noritada Kobayashi, Satoshi Ōmura, Hideaki Hanaki

J Antibiot (Tokyo) 2023; 76(8): 481–488. Published online 2023 Apr 25. doi: 10.1038/s41429-023-00623-0

PMCID:: PMC10127164

Abstract Article PDF–1.3M

Select item 944245510.

Potential therapeutic effects of Ivermectin in COVID-19

Nastaran Barati, Seyedmousa Motavallihaghi, Banafsheh Nikfar, Shahla Chaichian, Amir Abbas Momtazi-Borojeni

Exp Biol Med (Maywood) 2022 Aug; 247(15): 1388–1396. Published online 2022 Jun 10. doi: 10.1177/15353702221099579

PMCID:: PMC9442455

Abstract Article PDF–818K

Select item 777872311.

Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes

Harpinder Kaur, Nishant Shekhar, Saurabh Sharma, Phulen Sarma, Ajay Prakash, Bikash Medhi

Pharmacol Rep. 2021; 73(3): 736–749. Published online 2021 Jan 3. doi: 10.1007/s43440-020-00195-y

PMCID:: PMC7778723

Abstract Article PDF–1.7M

Select item 920613712.

Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations

Kunlakanya Jitobaom, Chompunuch Boonarkart, Suwimon Manopwisedjaroen, Nuntaya Punyadee, Suparerk Borwornpinyo, Arunee Thitithanyanont, Panisadee Avirutnan, Prasert Auewarakul

BMC Pharmacol Toxicol. 2022; 23: 41. Published online 2022 Jun 18. doi: 10.1186/s40360-022-00580-8

PMCID:: PMC9206137

Abstract Article PDF–4.1M

Select item 808882313.

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Pierre Kory, Gianfranco Umberto Meduri, Joseph Varon, Jose Iglesias, Paul E. Marik

Am J Ther. 2021 May-Jun; 28(3): e299–e318. Published online 2021 Apr 22. doi: 10.1097/MJT.0000000000001377

Correction in:: Am J Ther. 2021 Nov-Dec; 28(6): e813.

Expression of Concern in:: Am J Ther. 2022 Mar-Apr; 29(2): e231.

PMCID:: PMC8088823

Abstract Article PDF–976K

Select item 835090314.

Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin

Guilherme Dias de Melo, Françoise Lazarini, Florence Larrous, Lena Feige, Etienne Kornobis, Sylvain Levallois, Agnès Marchio, Lauriane Kergoat, David Hardy, Thomas Cokelaer, Pascal Pineau, Marc Lecuit, Pierre‐Marie Lledo, Jean‐Pierre Changeux, Hervé Bourhy

EMBO Mol Med. 2021 Aug 9; 13(8): e14122. Published online 2021 Jul 12. doi: 10.15252/emmm.202114122

PMCID:: PMC8350903

Abstract Article PDF–2.7M

Select item 785315515.

Ivermectin: An Anthelmintic, an Insecticide, and Much More

Richard J. Martin, Alan P. Robertson, Shivani Choudhary

Trends Parasitol. Author manuscript; available in PMC 2022 Jan 1.

Published in final edited form as: Trends Parasitol. 2021 Jan; 37(1): 48–64. Published online 2020 Nov 11. doi: 10.1016/j.pt.2020.10.005

PMCID:: PMC7853155

Abstract Article PDF–1.9M

Select item 744917616.

Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques

Pattaraporn Vanachayangkul, Rawiwan Im-erbsin, Anchalee Tungtaeng, Chanikarn Kodchakorn, Alison Roth, John Adams, Chaiyaporn Chaisatit, Piyaporn Saingam, Richard J. Sciotti, Gregory A. Reichard, Christina K. Nolan, Brandon S. Pybus, Chad C. Black, Luis A. Lugo-Roman, Matthew D. Wegner, Philip L. Smith, Mariusz Wojnarski, Brian A. Vesely, Kevin C. Kobylinski

Antimicrob Agents Chemother. 2020 Sep; 64(9): e00741-20. Prepublished online 2020 Jul 13. Published online 2020 Aug 20. doi: 10.1128/AAC.00741-20

PMCID:: PMC7449176

Abstract Article PDF–1.4M

Select item 1098176117.

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes

Gail Hayward, Ly-Mee Yu, Paul Little, Oghenekome Gbinigie, Milensu Shanyinde, Victoria Harris, Jienchi Dorward, Benjamin R. Saville, Nicholas Berry, Philip H. Evans, Nicholas P.B. Thomas, Mahendra G. Patel, Duncan Richards, Oliver V. Hecke, Michelle A. Detry, Christina Saunders, Mark Fitzgerald, Jared Robinson, Charlotte Latimer-Bell, Julie Allen, Emma Ogburn, Jenna Grabey, Simon de Lusignan, FD Richard Hobbs, Christopher C. Butler, PRINCIPLE Trial Collaborative Group

J Infect. 2024 Apr; 88(4): None. doi: 10.1016/j.jinf.2024.106130

PMCID:: PMC10981761

Abstract Article

Select item 824825218.

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Andrew Bryant, Theresa A. Lawrie, Therese Dowswell, Edmund J. Fordham, Scott Mitchell, Sarah R. Hill, Tony C. Tham

Am J Ther. 2021 Jul-Aug; 28(4): e434–e460. Published online 2021 Jun 21. doi: 10.1097/MJT.0000000000001402

Expression of Concern in:: Am J Ther. 2022 Mar-Apr; 29(2): e232.

PMCID:: PMC8248252

Abstract Article PDF–2.5M

Select item 729014319.

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Fatemeh Heidary, Reza Gharebaghi

J Antibiot (Tokyo) 2020; 73(9): 593–602. Published online 2020 Jun 12. doi: 10.1038/s41429-020-0336-z

PMCID:: PMC7290143

Abstract Article PDF–629K

Select item 829918720.

Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study

Suzan M. Mansour, Rehab N. Shamma, Kawkab A. Ahmed, Nirmeen A. Sabry, Gamal Esmat, Azza A. Mahmoud, Amr Maged

Int Immunopharmacol. 2021 Oct; 99: 108004. Published online 2021 Jul 23. doi: 10.1016/j.intimp.2021.108004

PMCID:: PMC8299187

Abstract Article PDF–9.0M

<< First< Prev

Page of 216

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for Ivermectin SARS

Fig. 4

Ivermectin contact profile with SARS CoV-2 proteins a S1-RBD, b S2 fusion domain, c N protein NTD and d CL protease

Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes

Pharmacol Rep. 2021;73(3):736-749.
Figure 1.Summary of patient characteristics included in the mITT population (n=96).

Study CONSORT diagram for the ivermectin analysis. *Prescreening occurred in the hospitals’ Acute Respiratory Infection (ARI) units. Potentially eligible participants (based on age, duration of symptoms, reported comorbidities, and a willingness to consider study participation) were selected by the ARI Nurses to be contacted by the study team. As a result, a high proportion of those assessed for eligibility participated in the study. **SARS CoV-2 Antigen Test Kit (STANDARD Q COVID-19 Ag Test, SD Biosensor, Suwon-si, Republic of Korea). mITT, modified intention-to-treat.

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

eLife. 2023;12:e83201.
Fig. 4Synchronized infections were conducted for a viral spread as described in Materials and Methods. Each curve shows a dose–response to the indicated 2 tested compounds (color-coded; key inset). The results are presented as the PFU formed in the presence of the drug as log(inhibitor) vs. normalized response (percent inhibition) -- variable slope. Standard deviations for each observed concentration in triplicate are represented as error bars. A) SARS CoV-2 anti-viral entry assay. Synchronized infections were conducted for viral entry as described in Materials and Methods. Each curve shows a dose–response to the indicated 2 tested compounds (color-coded; key inset). At 95% CI; ivermectin showed log IC50 = 0.4317 and Std. error for log IC50 0.04589. Compound IV showed log IC50 = 0.2979 and Std. error for log IC50 0.02746; and B) SARS-CoV-2 anti-viral spread assay. At 95% CI; ivermectin showed log IC50 = 0.7792 and Std. error for log IC50 0.01854. Compound IV showed log IC50 = 0.7961 and Std. error for log IC50 0.02272.

A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silico and in vitro investigations

RSC Med Chem. 2021 Oct 20;12(10):1757-1764.
Figure 2

Replication cycle of SARS CoV-2 in the host cell. Entry of the virus into the host cell is mediated through its interaction with Angiotensin converting enzyme receptor 2. The illustration summarises the potential sites of action of various drugs that are used in COVID -19. (A) Hydroxychloroquine and chloroquine inhibits virus entry into the cell by changing the glycosylation of ACE receptor (B) Remdesivir and Favipiravir inhibit the RNA polymerase (C) Azithromycin inhibits mRNA expression and protein production, it is also immunomodulatory and decreases inflammatory response (D) Ivermectin inhibits the interaction between the viral integrase protein (IN) and the importin (IMP) α/β1 heterodimer responsible for IN nuclear import (Not shown as a part of viral replication cycle). (E) Lopinavir, Ritonavir inhibit the protease enzyme

The Socially Distanced Social Animal – In The New Covid-19 Era

Ann Indian Acad Neurol. 2020 Apr;23(Suppl 1):S1-S4.